Paper Review Records
All Paper Review Records
5 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
110
days
Integrating clinical and genomic features to predict response to neoadjuvant therapy in microsatellite-stable rectal cancer
Authors
Lijie Zhang; Jingwen Wang; Juefeng Wan; Yan Wang; Hui Zhang; Yaqi Wang; Fan Xia; Lijun Shen; Zhen ZhangShow moreShow less
Affiliations
1. Department of Radiation Oncology, 89667Fudan University Shanghai Cancer Center, Shanghai, China; 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; 3. Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China; 4. Shanghai Key Laboratory of Radiation Oncology, Shanghai, China; 5. Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, ChinaShow moreShow less
174
days
Chemotherapy relative dose intensity and survival outcomes in pediatric and adolescent locoregionally advanced nasopharyngeal carcinoma: A retrospective cohort study
Authors
Zi-Xuan Chen; Ye-Hao Zou; Rui-Ling Xie; Ling-Ling Zhang; Chao Lin; Rui SunShow moreShow less
Affiliations
1. Department of Nasopharyngeal Carcinoma, 71067Sun Yat-sen University Cancer Center, Guangzhou, China; 2. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 71067Sun Yat-sen University Cancer Center, Guangzhou, China; 3. Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 71067Sun Yat-sen University Cancer Center, Guangzhou, China; 4. Department of Radiation Oncology, 117890FuJian Medical University Union Hospital, Fuzhou City, Fujian Province, ChinaShow moreShow less
161
days
Risk stratification and boost dose optimization for locoregionally advanced nasopharyngeal carcinoma with residual lesions based on clinical stage and post-radiotherapy EBV DNA
Authors
Xinyi Hong; Yi Li; Chaoying Lin; Jianxian Chen; Haosheng Zhang; Weijian Liu; Lanxin Lin; Zongying Qian; Sihan Lin; Yuhui Pan; Sufang QiuShow moreShow less
Affiliations
1. 74551Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China; 2. Sanya People’s Hospital, West China (Sanya) Hospital, Sichuan University, Sanya, China; 3. NHC Key Laboratory of Cancer and Metabolism, 66552Fujian Cancer Hospital, Fuzhou, Fujian, ChinaShow moreShow less
140
days
Historical evaluation of clinical outcomes and safety following isolated limb perfusion for unresectable melanoma: Real-world data from the Mannheim Cancer Center
Authors
Danai-Dionysia Kanatoula; Sebastian A. Wohlfeil; Corinne Hübers; Janna Eith; Jens Jakob; Peter Hohenberger; Jochen UtikalShow moreShow less
Affiliations
1. Department of Dermatology, Venereology, and Allergology, 36642University Medical Center and Medical Faculty Mannheim, Heidelberg University, and Center of Excellence in Dermatology, Mannheim, Germany; 2. Skin Cancer Unit, 28333German Cancer Research Center (DKFZ), Heidelberg, Germany; 3. DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany; 4. Department of Surgery, Medical Faculty Mannheim, Sarcoma Unit, 36642University Medical Center Mannheim, Heidelberg University, Mannheim, GermanyShow moreShow less
154
days
Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33—REGAL study
Authors
Davide Bimbatti; Cecilia Nasso; Domiziana Aspden; Sebastiano Buti; Ludovica Antonj; Alessio Signori; Elena Verzoni; Cristian Lolli; Marilena Di Napoli; Martina Fanelli; Miriam De Lucia; Cristina Masini; Giandomenico Roviello; Daniela Arduini; Roberto Filippi; Alessia Mennitto; Mariella Sorarù; Giovanni Bozza; Luigi Formisano; Carlo Messina; Lucia Bonomi; Annalisa Guida; Emanuela Fantinel; Sarah Scagliarini; Maria Giuseppa Vitale; Silvia Chiellino; Brigida Anna Maiorano; Filippo Maria Deppieri; Paolo Andrea Zucali; Alessia Cavo; Claudia Caserta; Francesca La Russa; Vincenza Conteduca; Francesca Maines; Silvia Zai; Francesco Pierantoni; Massimiliano Icardi; Pasquale Rescigno; Fabrizio Di Costanzo; Giuseppe Luigi Banna; Sara Elena RebuzziShow moreShow less
Affiliations
1. Oncology 1 Unit, Istituto Oncologico Veneto IOV–IRCCS, Padua, Italy; 2. Medical Oncology, Ospedale Santa Corona, Pietra Ligure, Italy; 3. University of Turin, A.O.U. Città della Salute e della Scienza di Torino, Ospedale Molinette, Turin, Italy; 4. Medical Oncology Unit, University Hospital of Parma, Parma, Italy; 5. Medicine and Surgery Department, University of Parma, Parma, Italy; 6. Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 7. Department of Health Sciences, Section of Biostatistics, University of Genova, Via Pastore 1, Genoa 16132, Italy; 8. IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, Genoa 16132, Italy; 9. Oncologia Medica Genitourinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 10. Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori,” Meldola, Italy; 11. Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy; 12. Department of Medical Oncology, Department of Medicine (DAME), University of Udine, Udine, Italy; 13. Unit of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy; 14. Medical Oncology. Comprehensive Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy; 15. Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Florence, Italy; 16. Università Cattolica del Sacro Cuore, Facoltà di Medicina e Chirurgia, Rome, Italy; 17. Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 18. Medical Oncology 1U, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy; 19. Department of Medical Oncology, Azienda Ospedaliera Universitaria “Maggiore Della Carità,” Novara, Italy; 20. U.O. Oncologia, Ospedale di Camposampiero, Camposampiero, Italy; 21. Medical Oncology IRCSS CROB, Rionero in Vulture, Italy; 22. Department of Clinical Medicine and Surgery at University of Naples Federico II, Naples, Italy; 23. Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy; 24. Medical Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy; 25. Medical Oncology Unit, Santa Maria Hospital, Terni, Italy; 26. Department of Oncology, Azienda Ospedaliera Universitaria Integrata di Verona, University of Verona, Verona, Italy; 27. Deparment of Medical Oncology, AORN “A. Cardarelli,” Naples, Italy; 28. Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy; 29. Medical Oncology Unit, IRCCS Policlinico San Matteo, Pavia, Italy; 30. Department of Medical Oncology, IRRCS San Raffaele Hospital, Milan, Italy; 31. Medical Oncology Unit, AULSS 3 Serenissima, Mestre-Venice, Italy; 32. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; 33. Department of Oncology, IRCCS, Humanitas Clinical and Research Center, Rozzano, Milano, Italy; 34. Oncology Unit, ASL3-Villa Scassi Hospital, Genoa, Italy; 35. Oncology Unit, Santa Maria della Misericordia Hospital Perugia, Italy; 36. Department of Oncology, Ospedale San Bortolo, Vicenza, Italy; 37. Unit of Medical Oncology and Biomolecular Therapy and CREATE Center for Research and Innovation in Medicine, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy; 38. Medical Oncology, Santa Chiara Hospital, Trento, Italy; 39. Medical Oncology Unit, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; 40. Oncology 3 Unit, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy; 41. Medical Oncology Unit 2, Ospedale Molinette, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy; 42. Department of Oncology, Candiolo Cancer Institute FPO-IRCCS, Turin, Italy; 43. Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK; 44. Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK; 45. Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UKShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days